<ARTICLE>                     5
<LEGEND>
     This schedule  contains summary  financial  information  extracted from ICN
Pharmaceuticals,   Inc.'s  March  31,  1999  Consolidated   Condensed  Financial
Statements  and is qualified  in its  entirety by  reference  to such  financial
statements.
</LEGEND>
<MULTIPLIER>                                   1,000
       
                             
<PERIOD-TYPE>                   3-mos
<FISCAL-YEAR-END>                          Dec-31-1999
<PERIOD-START>                             Jan-01-1999
<PERIOD-END>                               Mar-31-1999
<CASH>                                         110,847
<SECURITIES>                                         0
<RECEIVABLES>                                  230,717
<ALLOWANCES>                                   (46,778)
<INVENTORY>                                    123,141
<CURRENT-ASSETS>                               445,463
<PP&E>                                         384,297
<DEPRECIATION>                                 (59,495)
<TOTAL-ASSETS>                               1,355,117
<CURRENT-LIABILITIES>                          184,750
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          1
<COMMON>                                           774
<OTHER-SE>                                     608,218
<TOTAL-LIABILITY-AND-EQUITY>                 1,355,117
<SALES>                                        160,246
<TOTAL-REVENUES>                               176,074
<CGS>                                           66,396
<TOTAL-COSTS>                                   66,396
<OTHER-EXPENSES>                                 2,242
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              13,100
<INCOME-PRETAX>                                 26,059
<INCOME-TAX>                                     4,780
<INCOME-CONTINUING>                             22,619
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    22,619
<EPS-PRIMARY>                                      .29
<EPS-DILUTED>                                      .28